Loading...

XOMA XOMA ROYALTY CORP Company Mergers 8-K Filing

XM R

XM

XOMA ROYALTY CORP

(XOMA)

2026 8-K

Annual Meeting Report

Merger Completion

Merger Agreement Details

Financial Results Released

Corporate Presentation Update

Merger Completed

Asset Acquisition Update

Management Change

Corporate Presentation Update

Acquisition Completed

Acquisition Completed

Financial Update

Stock Sales Agreement

Correction Filing

Merger Completion

Merger Completed

Financial Results Report

Change of Jurisdiction

Financial Statements

Financial Results

Acquisition Update

Merger Announcement

Q3 Financial Results

Royalty Purchase

Q2 2024 Results

Acquisition of Kinnate Biop...

Sale of Priority Review Vou...

Annual Meeting of Stockholders

Financial Results Announcement

Completion of Acquisition

Merger Agreement

Appointment of CEO

Loan Agreement with Blue Ow...

Financial Results Announcement

Termination of License Agre...

Payment Received

Financial Results Announcement

Product Discontinuation

Acquisition of Assets and R...

Annual Meeting Approval

Financial Results Announcement

Acquisitions and mergers

Financial Results Announcement

Appointment of Owen Hughes ...

External Links:

XOMA Royalty Corp announced on May 16, 2026, that it has amended its merger agreement with Ligand Pharmaceuticals to include a new holding company, XOMA Royalty Holdings Corporation. This is a significant event for the company as it progresses in the reorganization process.

AI Assistant

XOMA ROYALTY CORP

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.